A
Alan D. Smith
Researcher at Eisai
Publications - 17
Citations - 1029
Alan D. Smith is an academic researcher from Eisai. The author has contributed to research in topics: Lenvatinib & Pembrolizumab. The author has an hindex of 6, co-authored 17 publications receiving 234 citations.
Papers
More filters
Journal ArticleDOI
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert J. Motzer,Boris Alekseev,Sun Young Rha,Camillo Porta,Masatoshi Eto,Thomas Powles,Viktor Grünwald,Thomas E. Hutson,Evgeny Kopyltsov,María José Méndez-Vidal,Vadim Kozlov,Anna Alyasova,Sung Hoo Hong,Anil Kapoor,Teresa Alonso Gordoa,Jaime R. Merchan,Eric Winquist,Pablo Maroto,Jeffrey C. Goh,Miso Kim,Howard Gurney,Vijay Patel,Avivit Peer,Giuseppe Procopio,Toshio Takagi,Bohuslav Melichar,Frederic Rolland,Ugo De Giorgi,Shirley Wong,Jens Bedke,Manuela Schmidinger,Corina E. Dutcus,Alan D. Smith,Lea Dutta,Kalgi Mody,Rodolfo F. Perini,Dongyuan Xing,Toni K. Choueiri +37 more
TL;DR: In this article, Lenvatinib in combination with pembrolizumab or everolimus has been shown to have activity against advanced renal cell carcinoma (RCC).
Journal ArticleDOI
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Chung-Han Lee,Amishi Yogesh Shah,Drew W. Rasco,Arpit Rao,Matthew H. Taylor,Christopher Di Simone,James J. Hsieh,Alvaro Pinto,David R. Shaffer,Regina Gironés Sarrió,Allen Lee Cohn,Nicholas J. Vogelzang,Mehmet Asim Bilen,Sara Gunnestad Ribe,Musaberk Goksel,Øyvind Krohn Tennøe,Donald A. Richards,Randy F. Sweis,Jay Courtright,Daniel Heinrich,Sharad Jain,Jane Wu,Emmett V. Schmidt,Rodolfo F. Perini,Peter Kubiak,Chinyere E. Okpara,Alan D. Smith,Robert J. Motzer +27 more
TL;DR: Eisai et al. as discussed by the authors evaluated the combination of lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma (RCC) and showed encouraging antitumour activity and manageable safety profile.
Journal ArticleDOI
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: Study design and rationale
Viktor Grünwald,Thomas Powles,Toni K. Choueiri,Thomas E. Hutson,Camillo Porta,Masatoshi Eto,Cora N. Sternberg,Sun Young Rha,Cixin S He,Corina E. Dutcus,Alan D. Smith,Lea Dutta,Kalgi Mody,Robert J. Motzer +13 more
TL;DR: The rationale and design of the CLEAR study, a three-arm Phase III trial comparing lenvatinib plus everolimus and lenvarinib plus pembrolizumab versus sunitinib monotherapy for first-line treatment of RCC, are described.
Journal ArticleDOI
Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC).
Chung-Han Lee,Amishi Yogesh Shah,James J. Hsieh,Arpit Rao,Alvaro Pinto,Mehmet Asim Bilen,Allen Lee Cohn,Christopher Di Simone,David R. Shaffer,Regina Gironés Sarrió,Sara Gunnestad Ribe,Jane Wu,Emmett V. Schmidt,Rodolfo F. Perini,Peter Kubiak,Alan D. Smith,Robert J. Motzer +16 more
TL;DR: LEN, a multikinase VEGFR inhibitor, plus everolimus is approved for advanced RCC after prior VEGF-targeted therapy and PEMBRO, an anti-PD-1 antibody, plus axitinib is approved as first-line RCC treatment.
Journal ArticleDOI
A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer
Vicky Makker,Nicoletta Colombo,Antonio Casado Herraez,Alessandro D. Santin,Emeline Colomba,David Miller,Keiichi Fujiwara,Sandro Pignata,Sally Baron-Hay,Isabelle Ray-Coquard,Ronnie Shapira-Frommer,Kimio Ushijima,Jun Sakata,Kan Yonemori,Yong Man Kim,Eva Guerra,Ulus Ali Sanli,Mary McCormack,Jie Huang,Alan D. Smith,Stephen Michael Keefe,Lea Dutta,Robert Orlowski,Domenica Lorusso +23 more
TL;DR: The phase III study results of LEN + pembro vs treatment of physician's choice (TPC) following platinum-based therapy in pts with advanced endometrial cancer (aEC) showed lenvatinib (LEN) + pembrolizumab (pembro) has efficacy in patients (pts).